Dana-Farber researchers reveal how p53 mutations hide cancer from immune cells

Researchers at the Dana-Farber Cancer Institute have identified why certain cancers, specifically those with p53 tumor-suppressor protein mutations, remain invisible to the immune system. The study, published in the journal Immunity, suggests that the challenge in immunotherapy is not always weak immune cells, but rather that these tumors fail to display the necessary molecular targets for T cells to recognize.

T cells do not interact with tumor DNA directly; instead, they inspect protein fragments called peptides presented on the cell surface via HLA molecules. This collection of fragments, known as the immunopeptidome, acts as a molecular window. In many cancers, these specific fragments never reach the surface or disappear too quickly, leaving the immune system with nothing to attack.

This finding is particularly significant for “cold” tumors—such as pancreatic, prostate, ovarian, certain breast cancers, and glioblastoma—which typically lack effective T-cell activity and are difficult to treat with standard immune-checkpoint drugs. The researchers propose a therapeutic strategy to modify what the cancer displays on its surface to make these tumors visible to the immune system.